Starbucks: Analysts Expect Q1 Revenues Of $7.95 Billion

Starbucks (NASDAQ: SBUX) will be reporting its first quarter financial results on February 1st before the market opens. Analysts have a consensus $121.97 12-month price target on the company, via a total of 37 analysts, with 9 analysts having strong buy ratings.

Nine analysts meanwhile have buy ratings, 18 analysts have a hold rating and a single analyst has a strong sell rating on the company. The street high comes from Kalinowski Equity Research with a $148 price target, and the lowest target sits at $96.

26 analysts have revenue estimates for the first quarter. The mean revenue estimate between all 26 analysts is $7.95 billion; this number has been flat since October 30th. The highest revenue estimate is $8.18 billion, while the lowest is $7.4 billion.

Altamira Gold Corp. — sponsored Sponsored · Altamira Gold Corp.

Onto EBITDA estimates, there are currently 18 analysts who have first-quarter EBITDA estimates. The mean is currently $1.66 billion, with this number having been revised downwards from $1.71 billion at the end of October. The street high estimate currently sits at $1.82 billion in EBITDA and the lowest is $1.49 billion.

Analysts estimate that quarterly earnings per share will come in at $0.80, with this number flat since the end of October. The street high sits at $0.90 and the lowest estimate is $0.72 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A $2.2B Gold Project Is Outgrowing Its Plan | Michael Henrichsen – Gold X2 Mining

Pay for the Copper, Get the Gold Free | Rob McEwen – McEwen Inc

This Gold Discovery Was Already Huge. Now It’s Becoming a Monster. | Goliath Resources

Recommended

This Gold Discovery Just Keeps Getting Bigger | Roger Rosmus – Goliath Resources

Cardiol Expands MAVERIC Trial to Up to 150 Patients After Reaching Enrollment Target Early

Related News

Ayr Strategies: PI Financial Initiates With $60 Price Target, Buy Rating

On January 20th, PI Financial became the fourth firm to cover Ayr Strategies’ (CSE: AYR.a)....

Sunday, January 24, 2021, 11:34:00 AM

Amazon: Analysts Expect $115.1 Billion In Q2 Revenue

Amazon.com Inc (NASDAQ: AMZN) will be reporting its second quarter financial results today after markets...

Thursday, July 29, 2021, 11:24:00 AM

Canaccord Lowers Else Nutrition Estimates After Disappointing Quarter

This past week, Else Nutrition (CSE: BABY) reported their second quarter financial results. The company...

Friday, September 3, 2021, 11:11:00 AM

DraftKings: Canaccord Lowers Estimates Based On Planned Future Reinvestment

DraftKings Inc. (Nasdaq: DKNG) earlier this month announced its third-quarter financial results. The company announced...

Sunday, November 20, 2022, 06:29:00 PM

Kinross Gold: Multiple Analysts Raise Price Target Following Dividend Resumption

This week Kinross Gold (TSX: K) announced that they would be issuing their first dividend...

Saturday, September 19, 2020, 03:47:00 PM